eLife (May 2020)
Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission
- Lucy Rivett,
- Sushmita Sridhar,
- Dominic Sparkes,
- Matthew Routledge,
- Nick K Jones,
- Sally Forrest,
- Jamie Young,
- Joana Pereira-Dias,
- William L Hamilton,
- Mark Ferris,
- M Estee Torok,
- Luke Meredith,
- The CITIID-NIHR COVID-19 BioResource Collaboration,
- Martin D Curran,
- Stewart Fuller,
- Afzal Chaudhry,
- Ashley Shaw,
- Richard J Samworth,
- John R Bradley,
- Gordon Dougan,
- Kenneth GC Smith,
- Paul J Lehner,
- Nicholas J Matheson,
- Giles Wright,
- Ian G Goodfellow,
- Stephen Baker,
- Michael P Weekes
Affiliations
- Lucy Rivett
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Sushmita Sridhar
- Wellcome Sanger Institute, Hinxton, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Dominic Sparkes
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Matthew Routledge
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Nick K Jones
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Sally Forrest
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Jamie Young
- Academic Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom
- Joana Pereira-Dias
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- William L Hamilton
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Mark Ferris
- Occupational Health and Wellbeing, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- M Estee Torok
- Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom; Department of Microbiology, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom
- Luke Meredith
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
- The CITIID-NIHR COVID-19 BioResource Collaboration
- Martin D Curran
- Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom
- Stewart Fuller
- National Institutes for Health Research Cambridge, Clinical Research Facility, Cambridge, United Kingdom
- Afzal Chaudhry
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Ashley Shaw
- National Institutes for Health Research Cambridge, Clinical Research Facility, Cambridge, United Kingdom
- Richard J Samworth
- Statistical Laboratory, Centre for Mathematical Sciences, Cambridge, United Kingdom
- John R Bradley
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; National Institutes for Health Research Cambridge Biomedical Research Centre, Cambridge, United Kingdom
- Gordon Dougan
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Kenneth GC Smith
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Paul J Lehner
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Nicholas J Matheson
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant, Cambridge, United Kingdom
- Giles Wright
- Occupational Health and Wellbeing, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
- Ian G Goodfellow
- ORCiD
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
- Stephen Baker
- Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- Michael P Weekes
- ORCiD
- Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom
- DOI
- https://doi.org/10.7554/eLife.58728
- Journal volume & issue
-
Vol. 9
Abstract
Significant differences exist in the availability of healthcare worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Over a 3 week period (April 2020), 1032 asymptomatic HCWs were screened for SARS-CoV-2 in a large UK teaching hospital. Symptomatic staff and symptomatic household contacts were additionally tested. Real-time RT-PCR was used to detect viral RNA from a throat+nose self-swab. 3% of HCWs in the asymptomatic screening group tested positive for SARS-CoV-2. 17/30 (57%) were truly asymptomatic/pauci-symptomatic. 12/30 (40%) had experienced symptoms compatible with coronavirus disease 2019 (COVID-19)>7 days prior to testing, most self-isolating, returning well. Clusters of HCW infection were discovered on two independent wards. Viral genome sequencing showed that the majority of HCWs had the dominant lineage B∙1. Our data demonstrates the utility of comprehensive screening of HCWs with minimal or no symptoms. This approach will be critical for protecting patients and hospital staff.
Keywords